PMG-A9 / Promedigen - LARVOL DELTA

A first-in-class orally bioavailable small molecule to overcome treatment resistance in hormone receptor-positive breast cancer (AACR 2026) - "CDK4/6 inhibitors combined with antiestrogens such as fulvestrant represent frontline therapy for hormone receptor-positive (HR+) breast cancer; however, therapeutic resistance inevitably emerges in a substantial subset of patients through diverse molecular mechanisms. In preclinical HR+ breast cancer xenograft models, PMG-A9 exhibits robust single-agent antitumor activity and pronounced synergy when combined with these agents. These findings highlight tumor-suppressor reactivation as a promising and broadly applicable therapeutic strategy with the potential to address resistance not only in HR+ breast cancer but also across a wide range of tumor types."

Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CCND1 • MYC

A first-in-class orally bioavailable small molecule tumor suppressor activator for the treatment of a wide range of cancers (AACR 2026) - "Notably, 5-fluorouracil (5-FU), a widely used first-line CRC therapy, is known to induce substantial upregulation of FoxM1. In preclinical CRC xenograft models, PMG-A9 exhibits robust single-agent antitumor efficacy and shows pronounced synergy when combined with multiple chemotherapeutic agents, including 5-FU, while effectively downregulating FoxM1 in vivo. These findings highlight tumor-suppressor reactivation as a promising, broadly applicable therapeutic strategy to improve treatment outcomes for CRC and, potentially, overcome drug resistance across diverse tumor types.*Corresponding authors: Hee-Sung Park; hee-sung.park@promedigen.com, Chakrapani Subramanyam; subramanyam@promedigen.com"

Colorectal Cancer • Oncology • Solid Tumor • FOXM1